Human papillomavirus vaccination: Ongoing challenges and future directions

Area of Science:

• Immunology
• Public Health
• Vaccinology

Background:

• Prophylactic human papillomavirus (HPV) vaccination has demonstrated significant efficacy, immunogenicity, and safety.
• Despite proven benefits, vaccine implementation and uptake remain challenging globally.
• Vaccination guidelines have evolved regarding age, dosing, and gender since 2006.

Purpose of the Study:

• To review the history and evolution of HPV vaccination.
• To identify barriers affecting vaccine implementation and uptake.
• To discuss current recommendations and future strategies for successful HPV immunization.

Main Methods:

• Literature review of studies on HPV vaccination efficacy, immunogenicity, and safety.
• Analysis of guideline updates from 2006 to present.
• Examination of recent FDA approval and ACIP recommendations for the 9-valent HPV vaccine.

Main Results:

• HPV vaccination is most effective when administered before sexual activity.
• Equal immunization of males and females, and catch-up vaccination for older adolescents and adults, are supported by research.
• The 9-valent HPV vaccine is now approved for ages 27-45, with ACIP recommending discussions for unvaccinated individuals in this age group.

Conclusions:

• Overcoming implementation barriers is crucial for maximizing HPV vaccine benefits.
• Expanded eligibility for the 9-valent HPV vaccine presents an opportunity to increase population-level protection.
• Continued research and strategic planning are essential for future success in HPV prevention through vaccination.